Any current/future capex/capital investment/strategic investment?

Current and future capex includes: - Rs.600 Crores investment in the 7ACA project (includes entire project outlay, working capital and fixed assets). - $10 million to $15 million investment planned for the Cefiderocol project. - Setting up a new sterile block commissioned in Nov 2023, targeting optimal utilization in next 6-12 months. - Capacity reconfiguration for oral products to shift from low-margin to higher-margin products, expected completion by end of H1 FY2025. - Backward integration for 7ACA, with engineering phase completed and pilot plant trials ongoing. - Plant designe

Future growth expectations in earnings/operating earnings/profits/EPS?

Orchid Pharma targets a long-term year-on-year revenue growth of **20% to 25%**. EBITDA margins are expected to remain stable around **40% plus/minus 2%**. Operating margins for specific projects like 7ACA are anticipated to be around **10%**, potentially allowing payback within 3 years post-operations. The company expects **high teens EBITDA margins** in the long term. Growth drivers include new product launches (e.g., Enmetazobactam, Cefiderocol), geographic expansion (US, Europe, LMICs), and improved domestic & export markets. Planned capacity expansions and debottlenecking efforts support

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected order book or pending orders for Orchid Pharma. Discussions focus on capacity, growth, product launches, and collaborations (notably with GARDP and Shionogi). Capacity setup for Cefiderocol at around 1 million vials initially, with scalable design to triple capacity if demand grows. Antimicrobial Solutions division is being developed, with expected launch in next 1-2 quarters. Growth is driven by multiple markets and new products; no specific order volume or backlog data shared. Launch of Cefiderocol expected in India in second

Orchid Pharma LtdQ3 FY24Pharmaceuticals & Biotechnology

Orchid Pharma Ltd Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹893.5P/E: 296.4Market Cap: ₹5.4K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Order

N/A

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

Future growth expectations for Orchid Pharma as per the provided transcript: - Anticipated quarter-on-quarter and year-on-year revenue growth of 20-25% over the next few years. - Growth driven by new customers, new markets, and new product launches, including off-patent products like Ceftazidime Avibactam. - Launch of new hospital sales division (Orchid Antimicrobial Solutions) expected in the next 1-2 quarters to boost hospital business revenues from FY2025. - Capacity optimization underway, including oral capacity rejig expected by end of H1 FY2025. - No large capital expenditures expected beyond ongoing projects (e.g., Cefiderocol, 7ACA). - Anticipated exponential growth for newly approved products such as Enmetazobactam in Europe and US starting Q1 next financial year. - Potential increase in capacity by debottlenecking without major capex, supporting growth. - Expansion plans with partners for antimicrobial products targeting 135 countries, especially LMICs.

Margin guidance

Category 3

Orchid Pharma targets a long-term year-on-year revenue growth of 20% to 25%.
EBITDA margins are expected to remain stable around 40% plus/minus 2%.
Operating margins for specific projects like 7ACA are anticipated to be around 10%, potentially allowing payback within 3 years post-operations.
The company expects high teens EBITDA margins in the long term.
Growth drivers include new product launches (e.g., Enmetazobactam, Cefiderocol), geographic expansion (US, Europe, LMICs), and improved domestic & export markets.
Planned capacity expansions and debottlenecking efforts support scaling revenues without major additional capex.
The hospital business and antimicrobial solutions division are expected to begin contributing commercially starting FY2025.
Profit after tax showed a substantial increase recently, indicating positive momentum in earnings growth.

See what Orchid Pharma Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

- Orchid Pharma does not anticipate any large capital expenditure for general growth apart from already announced projects like Cefiderocol and 7ACA. - There is no explicit mention of plans for new fundraising through debt or equity in the discussed period. - The company is focusing on stabilizing new projects and optimizing costs to improve margins. - Any future expansion, especially related to increased capacity (e.g., for the new antimicrobial product), would depend on market demand but is currently considered too early to quantify financial needs. - The firm is leveraging existing infrastructure and capacity with minimal additional investment planned. - Discussions with government schemes (PLI, GST benefits, interest subvention) help reduce financing burdens. Overall, no immediate plans for fresh fundraises were disclosed as of February 2024.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders for Orchid Pharma.
Discussions focus on capacity, growth, product launches, and collaborations (notably with GARDP and Shionogi).
Capacity setup for Cefiderocol at around 1 million vials initially, with scalable design to triple capacity if demand grows.
Antimicrobial Solutions division is being developed, with expected launch in next 1-2 quarters.
Growth is driven by multiple markets and new products; no specific order volume or backlog data shared.
Launch of Cefiderocol expected in India in second half of 2026, but regulatory pathways and commercialization strategies are still being finalized.
Pricing and marketing strategies are controlled by GARDP/Shionogi, affecting order volumes indirectly.
Overall, no concrete numbers on order book or pending orders were provided during the call.

See what Orchid Pharma Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Current and future capex includes:
- Rs.600 Crores investment in the 7ACA project (includes entire project outlay, working capital and fixed assets).
- $10 million to $15 million investment planned for the Cefiderocol project.
- Setting up a new sterile block commissioned in Nov 2023, targeting optimal utilization in next 6-12 months.
- Capacity reconfiguration for oral products to shift from low-margin to higher-margin products, expected completion by end of H1 FY2025.
- Backward integration for 7ACA, with engineering phase completed and pilot plant trials ongoing.
- Plant designed to allow capacity increase up to three times with minimal additional investment depending on demand.
- No need for large capex for general growth beyond announced projects like Cefiderocol and 7ACA.

Track Orchid Pharma Ltd — get its next earnings analysis in your feed

How does Orchid Pharma Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisOrchid Pharma Ltd

Rev 2Mar 3

See where Orchid Pharma Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Orchid Pharma Ltd rank in Pharmaceuticals & Biotechnology?

Compare Orchid Pharma Ltd against every Pharmaceuticals & Biotechnology company (Q3 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Orchid Pharma Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Bajaj Healthcare (Q2 FY27)
Operating Margin: Operating Margin = (EBITDA / Revenue from operations) × 100 = (2,770.29 / 14,791.49) × 100 ≈ 18.73% . Key results statement takeaways from Baj
Himalaya Nutravedics (Q2 FY27)
Reported revenue from operations for FY26: ₹4,306.8 lakhs, a year-on-year increase of 105.1% from ₹2,099.7 lakhs in FY25 (Page 22, 14, 5, 4). Key investor prese
Granules India (Q2 FY27)
Granules plans to invest about ₹2,000 crore in organic capital expenditure over the next 3-4 years. Key concall takeaways from Granules India Ltd's Q2 FY27…
Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →